06.18.15
PAREXEL expanded its Perceptive MyTrials Data-Driven Monitoring (DDM) solution with next generation risk-based monitoring capabilities allowing clients to perform cross-study analysis of quality, risk, and monitoring work effort by combining analytics, reporting and monitoring activity into a single solution.The enhancement aims to increase a drug developer's ability to demonstrate oversight and control of site-related risk, quality, and performance.
"Centralized monitoring methods are being encouraged by the U.S. Food and Drug Administration (FDA) and other regulatory bodies. By combining our DDM and monitoring solution, PAREXEL clients now have the ability to bridge real-time information gaps between centralized analysts and in-the-field monitoring teams, reducing risk, ensuring documentation, and increasing quality," said Drew Garty, senior director, product management, PAREXEL.
The Perceptive MyTrials Data-Driven Monitoring solution uses an algorithmic-based approach to clinical monitoring to determine risk and monitor workload, with the goal of enabling flexible and scalable decision-making.
"Centralized monitoring methods are being encouraged by the U.S. Food and Drug Administration (FDA) and other regulatory bodies. By combining our DDM and monitoring solution, PAREXEL clients now have the ability to bridge real-time information gaps between centralized analysts and in-the-field monitoring teams, reducing risk, ensuring documentation, and increasing quality," said Drew Garty, senior director, product management, PAREXEL.
The Perceptive MyTrials Data-Driven Monitoring solution uses an algorithmic-based approach to clinical monitoring to determine risk and monitor workload, with the goal of enabling flexible and scalable decision-making.